Skip to main content
. Author manuscript; available in PMC: 2022 Mar 15.
Published in final edited form as: AIDS. 2021 Mar 15;35(4):543–553. doi: 10.1097/QAD.0000000000002785

Figure 3. Tg6F attenuates increases in plasma and gut oxidized lipoproteins driven by HIV and/or ART in chronic treated HIV infection.

Figure 3.

TKO C57 (n=38) and NSG (n=52) humanized mice were constructed, infected with HIV and treated with ART, control transgenic tomato concentrate (EV) or Tg6F as described in Figure 1. Whole blood and small intestine from each mouse were collected, plasma and tissue homogenates were prepared and murine plasma and gut oxidized lipoproteins [oxidized High Density Lipoprotein (HDLox), oxidized Low Density Lipoprotein (LDLox) were determined in plasma of TKO and NSG BLT mice and homogenate of small intestine from TKO BLT mice as in methods by ELISA (A, B, D, E-H). HDLox (normalized ratio to control, no units) was determined in plasma of TKO BLT mice with a fluorometric method (C) as described in the supplemental material. Data represent box and whiskers with minimum, median and maximum values (n = 8–22 mice per group) of plasma HDLox (A-C), gut HDLox (D), plasma LDLox (E, F) and gut LDLox (G) in NSG (A, E) and TKO (B, C, D, F, G, H). The Mann-Whitney test was used to compare 2 groups (*p < 0.05, **p < 0.01, ***p < 0.001).